Speaker Profile

Chief Executive Officer, Exai Bio Inc.

Biography
Pat Arensdorf is co-founder and Chief Executive Officer of Exai Bio, a next-generation liquid biopsy company using cell-free RNA to enable the earlier and more accurate diagnosis of cancer. Previous to Exai Bio, he has been involved in the founding, strategy and executive management of several companies, including Bluestor Genomics, Critical Diagnostics, Diadexus (acquired by Diazyme), Immumetrix (acquired by CareDx), Tethys Bioscience (acquired by HDL), Intersect ENT (IPO), and First Medical (acquired by Sigma-Aldrich). Pat began his career in finance and strategic consulting in private equity. He received his bachelor's degree in Molecular Biology from Princeton and his masters from the Stanford GSB.


Clinical Dx Showcase:
Exai Bio Inc.

Exai Bio is a next-generation liquid biopsy company. The company's propriety RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way.

OncRNA: a Novel Liquid Biopsy Technology Platform
Orphan non-coding RNAs (oncRNAs) are a novel and previously unannotated class of small non-coding RNAs, and are observed in many types of cancer but not seen in normal tissue. OncRNAs enable a next-generation RNA-based liquid biopsy strategy for detecting cancer.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative